Abstract: “Cisplatin is a commonly used anticancer drug which is the first generation of platinum-based anticancer drugs developed. The cis configuration enables the binding of the coordination complex to one or two DNA strand(s) and thereby crosslinking the DNA strands triggering the cells to die in a programmed manner. Cisplatin is administered to patients intravenously as a short-term infusion in normal saline for chemotheraputic treatment to solid malignancies. It is used to treat various types of cancers which include sarcomas and some carcinomas such as small cell lung cancer, ovarian cancer, lymphomas, bladder cancer, cervical cancer, and germ cell tumours. It is found that cisplatin is particularly effective against testicular cancer with a cure rate of 10-85%. When administered into blood, cisplatin reacts with thiol containing proteins present in blood plasma thus reducing its bioavailability and increasing cytotoxicity. Cisplatin is associated with numerous side effects which include n”

Keywords: calcium carbonate nanoparticles, hollow and porous vaterite nanoparticles, cisplatin, encapsulation, targeted delivery, slow and steady release